Americans will have better access to popular weight-loss drugs Zepbound and Wegovy, after US President Donald Trump unveiled a deal with drugmakers Eli Lilly and Novo Nordisk.

Known as GLP-1 receptor agonists, the drugs have soared in popularity in recent years, but patient access has been a consistent problem because of their cost — around $500 a month for higher doses — and insurance coverage has been spotty. More than 100 million American adults are obese, according to federal estimates.

Coverage of the drugs will expand to Medicare patients starting next year, according to the administration, which said some lower prices will also be phased in for patients without coverage.

Starting doses of new, pill versions of the treatments also will cost $149 a month if they are approved.

"(It

See Full Page